How many people does AstraZeneca employ worldwide?

As at 31 December 2020, we employed approximately 76,100 people:

  • 44% in Emerging Markets (including China, Russia, Central & South America, Middle East & Africa and Other Asia Pacific)
  • 31% in Europe
  • 18% in the US
  • 7% in the Established Rest of World (including Japan, Canada, Australia & New Zealand)

Further detail can be found on page 70 of the latest Annual Report.

How many shares does AstraZeneca have outstanding?

The total number of shares in issue as at 31 December 2021 was 1,549,400,665.


AstraZeneca PLC publishes its total number of voting rights each month. These notifications can be found in the Stock exchange announcements.

On what stock exchange is AstraZeneca traded and what is the stock symbol?

AstraZeneca is traded on the London, Stockholm and Nasdaq exchanges. The symbol is AZN in all three markets.

What accounting convention does AstraZeneca adhere to?

AstraZeneca adheres to the International Financial Reporting Standards (IFRS) and International Accounting Standards (IAS) with appropriate conversion to US GAAP being shown in our financial statements.

What is AstraZeneca's current debt rating?

Please visit our Debt Investors page for details of AstraZeneca’s current debt rating.


What is AstraZeneca's CUSIP number for its ADRs traded on Nasdaq?


What is AstraZeneca's official accounting currency?

AstraZeneca reports in US dollars.

When was AstraZeneca PLC formed?

AstraZeneca was formed on 6 April 1999 through the merger of Astra AB of Sweden and Zeneca PLC of the United Kingdom.

Where can I find historical financial information on AstraZeneca?

This information can be found in the financial results section.

When will I receive my next dividend payment?

For information on dividends, please see the Dividends section of the FAQs.

Dividend policy


Can AstraZeneca pay my dividends directly into my bank or building society account?


Yes, it is possible to have your dividends paid directly into your bank or building society.

If your shares are held by a broker or nominee please contact them directly.

If you are a registered shareholder please contact the following:  

UK shareholders can click here to obtain the relevant form from the Equiniti Shareview website. Alternatively, contact Equiniti to request a form

  • US ADR holders should contact American Stock Transfer toll free on +1 (888) 697 8018 or outside the US on +1 (781) 575 4555
  • Swedish shareholders should contact your personal broker or if you hold a VPC account contact the VPC on +46 (0) 8 402 9000, alternatively contact Euroclear.

Contact details for Equiniti and Euroclear can be found here.



Does AstraZeneca have a dividend re-investment plan?

At present AstraZeneca does not have a dividend re-investment plan for Ordinary shareholders. Registered American Depositary Receipt holders may elect to have dividends reinvested via the DB Global Direct program. Please contact American Stock Transfer for further details on +1 888 697 8018.

I am a non-taxpayer; can I have my AstraZeneca dividends paid gross?

No, it is not possible to have your dividends paid gross.

Where can I find dividend information?

Please visit our dividend policy.

In which currency will my dividend be paid?

AstraZeneca pays the dividend in the currency corresponding to where the shares are listed.

Can I choose to receive my dividend in a different currency?

Holders of Ordinary Shares listed in London may be able to use Equiniti’s Overseas Payment Service to receive the dividend in a currency other than GBP. Contact Equiniti for details.

Registered shareholders

My personal details have changed - whom do I contact?

Who do I contact to:

  • request information on my account?
  • transfer stock?
  • request a share certificate replacement?

This will depend on where your shares are held:

If your shares are held by a broker or nominee please contact them directly.

If you are a registered shareholder please contact the following:

    UK shareholders should contact Equiniti.
    US shareholders should contact American Stock Transfer at [email protected].
    Swedish shareholders should contact your personal broker or if you hold a VPC account contact the VPC on +46 (0) 8 402 9000.

    Contact details for Equiniti can be found on the Shareholder information page under Shareholder forms.


I am a UK shareholder. How do I allocate my cost basis of AstraZeneca shares to my Syngenta distribution?

Please follow the link below to a summary of dividends paid in the form of Syngenta shares.

View UK cost basis information (opens in a new window).

I am a US shareholder. How do I allocate my cost basis of AstraZeneca shares to my Syngenta distribution?

Please follow the link below to a summary of dividends paid in the form of Syngenta shares.

View US cost basis information (opens in a new window).

I still hold Astra AB shares. What course of action should I take?

View a letter to Astra AB shareholders (opens in a new window).

A legal representative, Peter Haglund, has been appointed to act on behalf of minority shareholders. He can be contacted at Advokatfirman Sodermark, Box 14055, SE 104 40 Stockholm, Sweden, telephone +46 8 670 57 50 and fax +46 8 663 67 20.

What was the closing price of AstraZeneca PLC shares on its first trading day?

On 6 April 1999 (the first trading day of AstraZeneca PLC) the closing price was GBP 29.46.

What was the value of Zeneca shares when it demerged from ICI?

Shares in Zeneca Group PLC acquired on demerger from ICI will be treated as having a base cost for capital gains tax purposes ascertained by reference to the values of Zeneca and ICI shares on 1 June 1993 calculated in accordance with the provisions of Section 272 of the Taxation of Chargeable Gains Act 1992. The base cost of any holding of ICI Shares on that date will be adjusted on the same basis.

The relevant prices on The London Stock Exchange on 1 June 1993 were:

Zeneca - 625.75p and ICI - 631.75p

The base cost of the pre-merger ICI Shares were therefore split between the post-demerger Zeneca and ICI Shares in the following proportions:

Zeneca - 0.49761 and ICI - 0.50239

When Astra AB and Zeneca Group PLC merged how were the shares split / merged?

Astra AB and Zeneca Group PLC shares were merged on 6th April 1999.
1 Astra share : 0.5045 AstraZeneca share
1 Zeneca share : 1 AstraZeneca share

When did AstraZeneca demerge its agrochemical business?

AstraZeneca demerged its agrochemical business on 13 November 2000.


What is an ADS/ADR?

In the US, AstraZeneca’s Ordinary Shares are traded in the form of American Depositary Shares (ADSs), evidenced by American Depositary Receipts (ADRs), which are traded on Nasdaq under ticker symbol AZN. An ADS is a US dollar denominated form of equity ownership representing AstraZeneca’s underlying Ordinary Shares on deposit in the United Kingdom, and it confers the rights arising out of the underlying Ordinary Share including the right to vote at and attend general meetings of AstraZeneca and the right to receive dividends in US dollars.

What was the ADS ratio change and when did it take effect?

Historically one ADS has been equal to one Ordinary Share of AstraZeneca, a 1:1 ratio.

On 27 July 2015, a ratio change was effected so that two ADSs became equal to one Ordinary Share, a ratio of 2:1. ADS holders on the record date at the close of business on 22 July 2015 New York time received a distribution of one additional ADS for every one ADS held. No action was required by you to effect this change. These changes brought the AstraZeneca ADS price broadly in line with the market average and, as the ADS price reduced, it is thought that  the shares should be more attractive to individual shareholders and liquidity improved.

How has the ADS ratio change affected my shareholding in AstraZeneca?

The number of ADSs that were registered in your name at the close of business on 22 July 2015 New York time were doubled. While it is not possible to isolate the effect of the ratio change on the price of AstraZeneca’s ADSs from all the factors that affect the price, it is believed that the immediate effect was a reduction in price to approximately one-half of that prevailing immediately before the ratio change. The reduction in price, when coupled with the doubling of the ADSs held in your name should leave the value of your holding approximately the same immediately after, as it had been immediately before, the ratio change.

Will the ADS ratio change affect my dividends?

No. While the ratio change resulted in a halving of what would otherwise have been the dividend rate per share, your aggregate dividend remains the same as it would otherwise have been because your ADS holding has doubled.

Will I be subject to US federal income tax upon receipt of additional ADSs as a result of the ratio change?

No. The ratio change should have no US federal income tax implications for ADS holders, except that such holders should allocate to each additional ADS half of the holder’s tax basis in the original ADS with respect to which the additional ADS was received. If you hold ADSs as capital assets for US federal income tax purposes, your holding period for an additional ADS for capital gains tax purposes should include your holding period for the existing ADS with respect to which the additional ADS is received.

Are ADS holders charged a dividend fee?

Yes, beginning with the second interim dividend paid on 23 March 2015, holders of American Depositary Shares (ADSs) will be charged a total of $0.03 (3 cents) per ADS annually to cover costs related to the ADS programme. A fee of $0.01 (1 cent) will be deducted from the first interim dividend which is typically announced with second quarter and half year results and paid in September each year, and a fee of $0.02 (2 cents) will be deducted from the second interim dividend which is typically announced with fourth quarter and full year results and paid in March each year. 

Do other companies charge a dividend fee on their ADSs?

A large majority of dividend-paying FTSE100 companies that have an ADR/ADS programme charge dividend fees. AstraZeneca's dividend fee as a percentage of its dividends declared in respect of 2019 ($1.40 per ADR) was 2.1% compared to the FTSE100 sponsored ADR average of 6.9%

Share fraud warning

What is a ‘Boiler Room’ fraud?

A ‘Boiler Room’ fraud may take different forms but typically involves the use of high-pressure sales techniques and the promise of opportunities that appear too good to be true. AstraZeneca shareholders may be targeted by unsolicited phone calls or correspondence from ‘brokers’ who are often based overseas concerning investments and promising high financial returns. Unfortunately, the high profits promised never materialise and shareholders are often left significantly out of pocket. The ‘brokers’ are often both persistent and extremely persuasive with even experienced investors falling victim to the scams.  This type of fraud is called ‘boiler room’ fraud because of the high pressure sales techniques used by the ‘brokers’.  Around 5,000 people contact the Financial Conduct Authority (the ‘FCA’) each year regarding share fraud with victims losing an average of £20,000.

What should I do if I receive an unsolicited approach?

AstraZeneca shareholders are advised to be extremely cautious of any unsolicited approaches offering advice, free reports and offers to buy shares at a discount or sell at an inflated price.

In the event that you receive unsolicited contact regarding an investment opportunity the FCA offers the following advice, full details of which can be found on their website:

  • Reject any cold calls
  • Take the name of the person that has contacted you along with the full name and address of the organisation which they purport to work for
  • Check that the firm is correctly authorised by searching the FCA Register. The FCA strongly advise that individuals should only deal with financial services firms that are properly authorised by the FCA. You should verify the call using the contact details provided on the FCA Register
  • If you deal with an unauthorised firm you will not be eligible to receive payment under the Financial Services Compensation Scheme or have access to the Financial Ombudsman Service
  • Check whether the firm appears on the FCA Warning List
  • Seek impartial advice from a financial adviser before you make an investment
  • If a firm does not appear on the FCA Register or you are told by the ‘broker’ that the details are out of date contact the FCA on 0800 111 6768 or use the FCA reporting form which can be found here

If you believe that you have already paid money to share fraudsters you should contact ActionFraud on +44(0)300 123 2040.

Where can I find further information?

Further information on Boiler Room and share frauds can be found on the FCA website and on the ActionFraud website.

Where can I find further information?

Further information on Boiler Room and share frauds can be found on the FCA website and on the Action Fraud website.